Craig I Coleman

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Surgery
• Diabetes mellitus

His primary scientific interests are in Internal medicine, Meta-analysis, Randomized controlled trial, Atrial fibrillation and Confidence interval. His Internal medicine study combines topics from a wide range of disciplines, such as Diabetes mellitus, Endocrinology, Surgery and Cardiology. His Meta-analysis study incorporates themes from Gastroenterology, Odds, MEDLINE and Intensive care medicine.

His study in Randomized controlled trial is interdisciplinary in nature, drawing from both Adverse effect, Placebo, Clinical trial and Physical therapy. His Atrial fibrillation research is multidisciplinary, incorporating perspectives in Cardiac surgery and Anesthesia. The concepts of his Confidence interval study are interwoven with issues in Myocardial perfusion imaging, Single-photon emission computed tomography, Nuclear medicine, Cardiac PET and Stenosis.

His most cited work include:

• Statins and cancer risk: a meta-analysis. (503 citations)
• Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes (405 citations)
• Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States (332 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, In patient, Surgery, Cardiology and Anesthesia. His study in Atrial fibrillation, Myocardial infarction, Randomized controlled trial, Rivaroxaban and Warfarin is done as part of Internal medicine. His Atrial fibrillation research incorporates themes from Stroke, Odds ratio, Cardiothoracic surgery and Intensive care medicine.

In Randomized controlled trial, Craig I Coleman works on issues like Meta-analysis, which are connected to Confidence interval. His study looks at the relationship between Surgery and topics such as Strength of evidence, which overlap with Adverse outcomes. His Anesthesia research incorporates elements of Pulmonary embolism and Placebo.

He most often published in these fields:

• Internal medicine (55.03%)
• In patient (37.16%)
• Surgery (35.07%)

What were the highlights of his more recent work (between 2015-2021)?

• Internal medicine (55.03%)
• Rivaroxaban (14.68%)
• Atrial fibrillation (21.73%)

In recent papers he was focusing on the following fields of study:

Craig I Coleman mainly investigates Internal medicine, Rivaroxaban, Atrial fibrillation, Warfarin and Pulmonary embolism. His Internal medicine study frequently draws connections between related disciplines such as Cardiology. His research investigates the connection between Rivaroxaban and topics such as Discontinuation that intersect with problems in Risk factor.

His biological study deals with issues like Stroke, which deal with fields such as Subgroup analysis. His work deals with themes such as Anesthesia and Surgery, Gastrointestinal bleeding, Hemodialysis, which intersect with Warfarin. In his study, which falls under the umbrella issue of Confidence interval, Randomized controlled trial and MEDLINE is strongly linked to Meta-analysis.

Between 2015 and 2021, his most popular works were:

• Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. (96 citations)
• Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study (69 citations)
• Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack (59 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Surgery
• Diabetes mellitus

His primary areas of study are Internal medicine, Rivaroxaban, Atrial fibrillation, Warfarin and Cardiology. His work on Propensity score matching, Randomized controlled trial, Confidence interval and Meta-analysis as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines. His Randomized controlled trial research includes themes of Relative risk and Medical prescription.

His Meta-analysis study incorporates themes from Epidemiology and MEDLINE. His Rivaroxaban research incorporates elements of Venous thromboembolism, Emergency department, Emergency medicine, Anticoagulant and Pulmonary embolism. As part of the same scientific family, Craig I Coleman usually focuses on Atrial fibrillation, concentrating on Stroke and intersecting with Subgroup analysis.